See more : Southwest Airlines Co. (SWN.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Sun Pharma Advanced Research Company Limited (SPARC.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sun Pharma Advanced Research Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Q-Gold Resources Ltd. (QGLDF) Income Statement Analysis – Financial Results
- Shanghai Hugong Electric Group Co.,Ltd. (603131.SS) Income Statement Analysis – Financial Results
- Nurosene Health Inc. (MEND.CN) Income Statement Analysis – Financial Results
- Nanoform Finland Oyj (NANOFH.HE) Income Statement Analysis – Financial Results
- Voltamp Transformers Limited (VOLTAMP.NS) Income Statement Analysis – Financial Results
Sun Pharma Advanced Research Company Limited (SPARC.NS)
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 755.45M | 2.31B | 1.37B | 2.53B | 768.14M | 1.83B | 782.59M | 1.81B | 1.61B | 1.56B | 1.67B | 872.79M | 289.77M | 583.48M | 344.07M | 351.42M | 374.63M | 3.10M | 0.00 |
| Cost of Revenue | 1.99B | 1.72B | 1.27B | 2.06B | 1.93B | 1.60B | 1.44B | 1.71B | 1.38B | 1.21B | 80.08M | 93.05M | 74.16M | 76.82M | 67.63M | 93.78M | 68.62M | 3.10M | 0.00 |
| Gross Profit | -1.24B | 592.00M | 105.52M | 465.55M | -1.16B | 224.42M | -659.10M | 99.86M | 228.69M | 350.28M | 1.59B | 779.74M | 215.61M | 506.66M | 276.44M | 257.64M | 306.01M | 0.00 | 0.00 |
| Gross Profit Ratio | -163.91% | 25.65% | 7.69% | 18.40% | -151.55% | 12.27% | -84.22% | 5.52% | 14.18% | 22.49% | 95.21% | 89.34% | 74.41% | 86.83% | 80.34% | 73.31% | 81.68% | 0.00% | 0.00% |
| Research & Development | 4.79B | 4.53B | 3.24B | 3.88B | 3.87B | 1.48B | 3.21B | 3.04B | 2.24B | 1.91B | 1.34B | 1.04B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.54B | 1.32B | 695.23M | 519.34M | 439.21M | 560.33M | 484.28M | 47.14M | 35.58M | 23.28M | 533.65M | 418.73M | 472.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | -1.92B | 1.32B | 695.23M | 519.34M | 439.21M | 560.33M | 484.28M | 47.14M | 35.58M | 23.28M | 533.65M | 418.73M | 472.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -1.29M | 108.80M | 771.00K | 4.71M | 310.00K | 9.31M | 117.00K | -6.63M | 18.74M | -2.28M | -2.18M | -2.78M | 4.00K | 590.37M | 488.38M | 380.13M | 649.00K | 41.00K | 0.00 |
| Operating Expenses | 3.08B | 2.93B | 2.07B | 1.92B | 1.99B | 1.75B | 1.85B | 1.41B | 930.17M | 769.60M | 1.29B | 976.59M | 946.39M | 590.37M | 488.38M | 380.13M | 352.28M | 15.28M | 0.00 |
| Cost & Expenses | 4.87B | 4.65B | 3.33B | 3.99B | 3.92B | 3.35B | 3.29B | 3.12B | 2.31B | 1.98B | 1.37B | 1.07B | 1.02B | 667.20M | 556.01M | 473.91M | 420.89M | 18.38M | 0.00 |
| Interest Income | 254.76M | 75.95M | 14.10M | 8.97M | 29.32M | 31.36M | 6.36M | 116.47M | 7.32M | 27.59M | 39.00M | 7.19M | 5.77M | 3.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.90M | 76.30M | 133.29M | 106.50M | 26.75M | 939.00K | 1.23M | 18.20M | 21.45M | 2.18M | 55.97M | 39.51M | 2.74M | 1.28M | 1.75M | 2.43M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 125.11M | 117.71M | 101.62M | 109.23M | 94.81M | 75.52M | 81.85M | 82.40M | 75.79M | 72.40M | 35.72M | 33.96M | 31.62M | 29.86M | 25.99M | 18.36M | 12.67M | 1.00M | 0.00 |
| EBITDA | -3.73B | -2.03B | -1.80B | -1.30B | -3.00B | -1.38B | -1.89B | -1.09B | -599.78M | -317.84M | 437.72M | -148.70M | -687.95M | -53.94M | -187.70M | -101.70M | -33.31M | -17.35M | 0.00 |
| EBITDA Ratio | -493.94% | -88.04% | -134.98% | -51.63% | -399.73% | -79.36% | -309.00% | -60.87% | -37.32% | -20.72% | 23.27% | -18.38% | -237.46% | -9.23% | -54.04% | -29.63% | -8.97% | -560.46% | 0.00% |
| Operating Income | -4.12B | -2.15B | -1.97B | -1.46B | -3.15B | -1.52B | -2.51B | -1.31B | -701.47M | -419.32M | 302.16M | -196.85M | -730.78M | -83.72M | -211.94M | -122.49M | -46.26M | -18.38M | 0.00 |
| Operating Income Ratio | -544.71% | -93.14% | -143.47% | -57.68% | -410.02% | -83.18% | -320.44% | -72.49% | -43.49% | -26.92% | 18.09% | -22.55% | -252.20% | -14.35% | -61.60% | -34.85% | -12.35% | -592.84% | 0.00% |
| Total Other Income/Expenses | 246.72M | 10.61M | -73.23M | -54.37M | 25.51M | 66.87M | 537.77M | 117.35M | 4.34M | 26.90M | 41.08M | -28.09M | 8.46M | 11.16M | -1.75M | -5.37M | 649.00K | 50.00K | 0.00 |
| Income Before Tax | -3.87B | -2.23B | -2.03B | -1.51B | -3.12B | -1.45B | -1.97B | -1.20B | -699.92M | -395.20M | 343.24M | -224.95M | -722.32M | -85.00M | -215.44M | -124.91M | -45.62M | -18.34M | 0.00 |
| Income Before Tax Ratio | -512.05% | -96.45% | -148.19% | -59.75% | -406.70% | -79.53% | -251.73% | -66.44% | -43.40% | -25.38% | 20.55% | -25.77% | -249.28% | -14.57% | -62.61% | -35.55% | -12.18% | -591.52% | 0.00% |
| Income Tax Expense | 3.82M | 117.47M | 14.82M | 43.82M | -15.74M | -5.61M | 7.70M | 127.97M | 23.84M | 24.30M | 40.00M | 2.44M | 11.08M | 10.00K | 215.34M | -33.51M | 3.21M | 31.50M | 0.00 |
| Net Income | -3.87B | -2.23B | -2.03B | -1.51B | -3.12B | -1.45B | -1.97B | -1.20B | -699.92M | -395.20M | 303.24M | -224.95M | -722.32M | -85.01M | -215.53M | -91.41M | -48.83M | -49.84M | 0.00 |
| Net Income Ratio | -512.56% | -96.45% | -148.19% | -59.75% | -406.70% | -79.53% | -251.73% | -66.44% | -43.40% | -25.38% | 18.15% | -25.77% | -249.28% | -14.57% | -62.64% | -26.01% | -13.03% | -1,607.26% | 0.00% |
| EPS | -11.93 | -7.82 | -7.73 | -5.77 | -11.92 | -5.69 | -7.94 | -4.89 | -2.96 | -1.67 | 1.27 | -1.03 | -3.41 | -0.40 | -1.02 | -0.43 | -0.24 | -0.24 | 0.00 |
| EPS Diluted | -11.93 | -7.82 | -7.73 | -5.77 | -11.92 | -5.69 | -7.94 | -4.89 | -2.96 | -1.67 | 1.27 | -1.03 | -3.41 | -0.40 | -1.02 | -0.43 | -0.23 | -0.24 | 0.00 |
| Weighted Avg Shares Out | 324.57M | 284.70M | 263.14M | 262.05M | 262.05M | 255.60M | 248.08M | 246.17M | 236.69M | 236.68M | 238.28M | 219.41M | 211.96M | 212.02M | 212.02M | 212.02M | 203.88M | 212.02M | 43.47K |
| Weighted Avg Shares Out (Dil) | 324.52M | 284.70M | 263.14M | 262.05M | 262.05M | 255.60M | 248.08M | 246.17M | 236.69M | 236.68M | 238.28M | 219.41M | 211.96M | 212.02M | 212.02M | 212.02M | 212.02M | 212.02M | 43.47K |
Source: https://incomestatements.info
Category: Stock Reports